PA
RCKT icon

Profund Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Profund Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,066
Closed -$226K – 1232
2026
Q1 		$226K Buy
+63,066
New +$251K 0.01% 949
2025
Q2 		– Sell
-32,285
Closed -$215K – 1037
2025
Q1 		$215K Buy
32,285
+2,124
+7% +$21K 0.01% 869
2024
Q4 		$379K Buy
30,161
+4,436
+17% +$66.8K 0.01% 659
2024
Q3 		$475K Buy
25,725
+3,524
+16% +$72.2K 0.02% 550
2024
Q2 		$478K Sell
22,201
-28,947
-57% -$665K 0.02% 517
2024
Q1 		$1.38M Buy
51,148
+16,677
+48% +$474K 0.05% 267
2023
Q4 		$1.03M Sell
34,471
-6,390
-16% -$141K 0.04% 323
2023
Q3 		$837K Sell
40,861
-1,641
-4% -$29.8K 0.05% 326
2023
Q2 		$845K Sell
42,502
-13,014
-23% -$263K 0.05% 355
2023
Q1 		$951K Buy
+55,516
New +$1.09M 0.06% 312

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Profund Advisors's RCKT Position: Q2 2026 in Review

Profund Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 63,066 shares — an estimated $226K sold.

Profund Advisors first reported a position in RCKT in Q1 2023 and held it in 10 quarters. The position peaked at $1.38M in Q1 2024. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Profund Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Profund Advisors sold 63,066 Rocket Pharmaceuticals shares in Q2 2026, an estimated $226K.
  • Profund Advisors first reported a position in Rocket Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Profund Advisors's Rocket Pharmaceuticals position peaked at $1.38M in Q1 2024.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.